Results 151 to 160 of about 16,400 (167)

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients

JACC: CardioOncology, 2023
Weichuan Dong, Akiva Diamond, Paolo F Caimi   +2 more
exaly  

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Cancer Cell, 2017
Craig Thomas, John A Butman, Louis Staudt   +2 more
exaly  

Ibrutinib

Reactions Weekly, 2017
  +4 more sources

Cardiovascular Toxicities Associated With Ibrutinib

Journal of the American College of Cardiology, 2019
Javid Moslehi, Benedicte Lebrun-Vignes, Joe-Elie Salem   +2 more
exaly  

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Annals of Oncology, 2017
Jeffrey J Pu, Nicole Lamanna, B D Cheson   +2 more
exaly  

Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies

Journal of Thrombosis and Haemostasis, 2017
Joseph Shatzel, Owen Mccarty
exaly  

Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

Cancer, 2017
Zeev Estrov, Hagop Kantarjian, Susan O'Brien   +2 more
exaly  

Deuterated ibrutinib

2015
TUNG ROGER D, MORGAN ADAM J
openaire   +3 more sources

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

Clinical Infectious Diseases, 2018
M Lia Palomba, Susan Seo, Ying Taur
exaly  

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study

Hematological Oncology, 2017
Mehdi Hamadani, Jonathon Cohen, Narendranath Epperla   +2 more
exaly